Genmab — December 2024
-
Novo Nordisk to present new data from sickle cell disease and haemophilia trials at the 66th American Society of Hematology (ASH) annual meeting / Mim8 https://www.globenewswire.com/news-release/2024/12/03/2990557/0/en/Novo-Nordisk-to-present-new-data-from-sickle-cell-disease-and-haemophilia-trials-at-the-66th-American-Society-of-Hematology-ASH-annual-meeting.html
-
the GEN1042 trial in combination with radiotherapy / pembrolizumab set to Active, not recruiting - curious if we can get some info on that soonish https://clinicaltrials.gov/study/NCT05491317
-
Scancell Announces Genmab Exercises Option to a Second Commercial License Agreement https://www.investegate.co.uk/announcement/rns/scancell-holdings--sclp/second-commercial-license-agreement-with-genmab-/8588688
-
‘As bispecific antibodies change DLBCL treatment paradigm, Epkinly draws attention’
https://www.koreabiomed.com/news/articleView.html?idxno=25928 -
Genmab expands its pipeline with $630m Scancell deal https://pharmaphorum.com/news/genmab-expands-its-pipeline-630m-scancell-deal
-
Hej E L og andre. Trist at der er blevet så forholdsvist stille i Genmab chatten. Selv skriver jeg heller ikk som tidligere, men pyt med det. E L - du er mere end guld værd, og ikke kun “værdsat”. Håber virkelig du holder ved. Ligesom Solsen, Bulder og flere andre. Ingen flere nævnt desværre, men heller INGEN glemt. Håber virkelig både Genmab (aktien) og vi andre får gejsten igen. NB! Er selv i den grad fortsat i og omkring Genmab, men trist at positivt afkast kun hentes i spekulative dispositio
-
we used to keep ourselves busy with news on the royalty pipeline, Dara, amivantamab, teclistamab, talquetamab, kesimpta; there is still plenty of news on those, but the interest has disappeared here. Genmab's own pipeline does not produce that much news yet, data takes a long time.
-
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy https://www.nature.com/articles/s41408-024-01197-2
-
Uanset hvad vil jeg også gerne sige tusind tak EL for de mange informationer om Genmab. Som Solsen lige skrev, så er blot den sidste artikel jo monster interessant. Og der er sikkert andre end mig, der læser alle dine links, selv om vi er godt trætte af at vente på hexen...
-
I videoen her gennemgår vi Genmab med 3-PointPlaybook-strategien. Her kigger vi på følgende punkter:
- Er aktien solid?
- Er aktien godt prissat?
- Er timingen rigtig? https://proinvestor.com/boards/123320
-
Japanese acasunlimab safety trial Completed https://clinicaltrials.gov/study/NCT04937153?tab=history&a=17&b=18&compareMode=sideBySide#version-content-panel
-
https://x.com/Larvol/status/1864673303862157521/photo/1 promising #ClinicalTrials, most discussed among the oncologists on X - TRIMM-2 = Talq-Dara, Epcore= Epco, MajesTEC=Teclistamab, Auriga & AQUILA =Dara
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind